An Act to promote transparency and cost control of pharmaceutical drug prices
By Mr. Lesser, a petition (accompanied by bill, Senate, No. 696) of Eric P. Lesser, Diana DiZoglio and José F. Tosado for legislation to promote transparency and cost control of pharmaceutical drug prices. Health Care Financing.
Bill History
| Date | Branch | Action |
|---|---|---|
| 1/22/2019 | Senate | Referred to the committee on Health Care Financing |
| 1/22/2019 | House | House concurred |
| 3/27/2019 | Joint | Hearing scheduled for 04/11/2019 from 01:00 PM-04:00 PM in A-1 |
| 3/23/2020 | House | Reporting date extended to Friday May 1, 2020, pending concurrence |
| 3/26/2020 | Senate | Senate concurred |
| 4/29/2020 | House | Reporting date extended to Friday June 19, 2020, pending concurrence |
| 4/30/2020 | Senate | Senate concurred |
| 6/22/2020 | House | Reporting date extended to Thursday December 31, 2020, pending concurrence |
| 7/23/2020 | Senate | Ought NOT to pass (under Joint Rule 10) and placed in the Orders of the Day for the next session |
| 1/5/2021 | Senate | No further action taken |
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.